C ancer of the kidney is a common urological malignancy. A total of 4348 new cases were registered in the UK in 2004 and the incidence is rising. 1 Furthermore, it has considerable morbidity. About 30 per cent of patients present with metastases and a further third of patients develop metastases during their follow-up. Of those who present with metastases, the median survival is about one year. The five-year survival rate in patients with metastatic disease is 0-20 per cent. 2 However, about 70 per cent of patients present with localised or locally advanced disease. These patients are potentially curable by nephrectomy alone (Figure 1). 3 There have been a number of advances in the management of kidney cancer over the past 20 years. A greater understanding of the molecular genetics behind these tumours has led to the use of tailored therapeutic options, either in the adjuvant setting or with those patients presenting with metastases. These include chemotherapy, immunotherapy, tumour vaccines, gene therapy and allogeneic stem-cell transplantation.There have also been advances in surgical options. Nephron-sparing techniques have been developed and minimally invasive options using cryotherapy and radiofrequency ablation have been used successfully on carefully selected patients.Furthermore, several anatomical and histological characteristics, as well as emerging tumour markers, have led to more precise prognostic indicators of disease progression and survival.
Aetiology of renal cancerOf the renal cancers, renal cell carcinoma (RCC; an adenocarcinoma) constitutes approximately 85 per cent of all primary malignant tumours. Renal cell carcinoma occurs most commonly in the fifth to sixth decades and has a male to female ratio of 2:1.Renal cell carcinoma is essentially either hereditary or sporadic. Von Hippel-Lindau disease is a familial cancer syndrome in which individuals have a predisposition to develop tumours in multiple organs, including cerebellar haemangioblastoma, retinal angiomata and bilateral clear cell RCC.The aetiology of RCC that occurs de novo is relatively unknown. Occupational exposures, chromosomal aberrations and tumour-suppressor genes have all been implicated. Smoking appears to be the most common risk factor for the development of RCC. In a large prospective study carried out in the USA, 4 hypertension, a high body mass index and smoking appear independently to increase the risk of RCC. Similar findings were shown in a study from Japan. 5 However, apart from smoking, other causative agents remain controversial. Although the prognosis for patients with metastatic kidney cancer is poor, those presenting with localised disease are potentially curable with nephrectomy alone. The authors explain how newer, targeted therapeutic agents show promise of extending survival, and outline recent advances in surgical options and the development of more precise prognostic indicators of disease progression and survival.
TOM SWALLOW AND CHRIS ANDERSON